WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced that it signed a worldwide licensing agreement with Axxam SpA, a Milan, Italy-based company focused on early-stage discovery research and services for the life science industry, to become the exclusive provider of Axxam’s Photina® photoprotein technology to the drug discovery market. The Photina® technology is a luminescent cell-based assay platform optimized for screening important drug discovery targets, including G-protein coupled receptors (GPCRs) and ion channels. The terms of the agreement also provide for a formal research and development program between PerkinElmer and Axxam to develop additional Photina® GPCR and ion channel cell lines for use in high throughput screening and compound profiling. Axxam retains the rights to use the technology for its discovery services to third parties.
